A NEW IDEA ON MOMENTA, AFTER RECENT GAIN OF 74% THE DIP IS AN OPPORTUNITY TO ENTER AGAIN $MNTA $TEVA $PFE

A NEW IDEA ON MOMENTA, AFTER RECENT GAIN OF 74% THE DIP IS AN OPPORTUNITY TO ENTER AGAIN $MNTA $TEVA $PFE

This post was just published on ZYX Buy Change Alert.

On February 1st we issued a call to take profits on MNTA.  Depending upon how you traded, your profits would have been 74%.

We got out at the top.  Now the stock has fallen providing an opportunity to enter again.  The buy zone is $12 to $15.35, preferably below $14.31.  The stock is trading at $15.30 as of this writing. The target zone is $18 to $20, and $24 to $28 in the event of a buyout.  Stop zone on one-half of the position is $11 to $11.38.

Those who are not aggressive may consider accumulating only on a dip in the $12 range.

Recommended quantity is 30% of the full core position size.

MNTA is in the business of biosimilars.  In the world of biotechnology, biosimilars are just like generics in the traditional pharmaceutical world.  The difference is that making a biosimilar is much more difficult than making a generic.

Most of the movements in this stock result from ups and downs related to its drug Glatopa.  Glatopa is a biosimilar to Copaxone.  Copaxone is a highly popular MS drug from TEVA.

The drop in MNTA stock has resulted from an FDA warning letter to PFE.  PFE is the manufacturing partner for MNTA.

In our analysis, PFE should be able to resolve the issue in the near future.  However the risk in MNTA stock has increased as other companies are on its heels to develop a biosimilar for Copaxone.  For this reason those who are not aggressive need to wait for a dip into the $12 range; of course such a dip may never happen.  Those who are aggressive may consider scaling in by starting a very, very small position right here.  Please see Trade Management Guidelines.

 

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

INVESTORS OUGHT TO GET AHEAD OF TRUMP’S TAX-REFORM PUSH $SPY $AMZN $LUV $AAPL $MSFT $GOOG $SCHW $DGX $CVS $CSCO $WDC $CAT $PFE $RL $PAYX

President Trump’s economic adviser, Gary Cohn, said that starting this week the administration expects to launch a tax campaign that ...

BE FOREWARNED IF YOU ARE CHASING DIVIDENDS $TEVA $MYL $PRGO $RDY $ABX $MCK $CAH $ESRX

  Dividend-chasing is in vogue. Given low interest rates, many investors say they have no other choice. Such thinking leads to costly ...

WHAT COULD PUSH STOCKS EVEN HIGHER? TRUMP’S LATEST IDEA $AAPL $GLD $SLV $DUST $SPY $YM_F $PFE $GOOG $FB $SHOP

In my 30-plus years in the markets, I can safely say that most popular analysis methods do not work well. ...

UPDATE ON BIOTECH BEAR ETF LABD $LABD $LABU $PPH $PJP $PFE $JNJ $MRK $BMY $BBH $IBB $XBI

This post was just published on ZYX Buy Change Alert. In our divided country there are very few things on which Republicans and ...

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside ...

MOMENTA PHARMACEUTICALS JUMPS ON COPAXONE RULING, TAKE PROFITS AND EXIT THE POSITION IF STILL HOLDING $MNTA $MYL $TEVA

This post was published on ZYX Buy Change Alert. MNTA has an average price of $11.31.  As of this writing it is trading ...

MYLAN BENEFITING FROM COPAXONE $MYL $TEVA

This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug.  ...

BUY ON TRUMP? SELL ON TRUMP? WHO IS RIGHT? $GOOGL $AAPL $FB $INTC $MSFT $NVDA $C $BAC $JPM $MRK

Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, ...

WHAT PHARMA INVESTORS OUGHT TO DO AFTER DONALD TRUMP FIRES A SALVO $LABD $PFE $JNJ $MRK $BMY $LLY $PJP $IHE $PPH $IBB $XHI $BBH $BIS

Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. ...

FIVE UNPOPULAR, BUT PRUDENT, THINGS FOR INVESTORS TO DO NEAR DOW 20,000 $MLM $GIS $NVDA $SPY $AAPL $URI $MRK $JNJ $BMY $LLY $AVGO $INTC $ORCL

  I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one ...

TWO RARE CHART OCCURRENCES SHOWING PANIC SAYS DOW 20,000 MAY END THE MOVE $SPY $IWM $PFE $QQQ $UNH

Only three days ago I predicted that a performance chase is on. Wednesday’s nearly 300-point move in the Dow Jones ...

PLAN ON MYLAN: TEVA PHARMACEUTICAL, TAX LOSS SELLING AND TRUMP $MYL $TEVA

This post was just published on ZYX Buy Change Alert. TEVA MYL is a generic drug manufacturer.  The earlier decline in the stock was ...

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely ...

SMART MONEY LIGHTLY STEPS INTO MYLAN $MYL $ENDP $IPXL $LCI $TARO $TEVA

This post was just published on ZYX Buy Change Alert. Algorithms at The Arora Report have been detecting smart money lightly stepping into ...

UPDATE ON MYLAN $MYL $TEVA $LCI $IPXL $ENDP $TARO

This post was just published on ZYX Buy Change Alert. All generic drug manufacturers are falling on the news that U. S. prosecutors ...

INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MEDIVATION BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $RARE $SGEN $TSRO $MDVN $PFE

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of ...

THE ARORA REPORT SUBSCRIBERS MAKE 143% ANNUALIZED RETURN ON MEDIVATION BUYOUT BY PFIZER $MDVN $PFE

This post was just published on ZYX Buy Change Alert. MDVN is the 113th company in our portfolio involved in M&A.  The Arora ...

GET AHEAD OF SUPREME COURT ON OBAMACARE, TAKE PROFITS AND REVIEW HEALTHCARE POSITIONS $CYH $THC $RAD $WBA $MOH $CNC $PRGO $MYL #OBAMACARE

This post was just published on ZYX Buy Change Alert. The Supreme Court is likely to make a ruling on Obamacare this ...

SMART MONEY SELLS INTO MYLAN RISE FOR A GOOD REASON $MYL $FRX $ACT $TEVA

Since the Feb. 18 announcement that Actavis would acquire Forest Laboratories for about $25 billion, which caused Forest Laboratories stock to leap ...

INDIA COURT RULING AGAINST NOVARTIS IS DARK OMEN FOR BIG PHARMA $NVS $LLY $BMY $MRK $JNJ $PFE

It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected ...

Follow

Get every new post delivered to your Inbox

Join other followers